|
1
|
Bray F, Ren JS, Masuyer E and Ferlay J:
Global estimates of cancer prevalence for 27 sites in the adult
population in 2008. Int J Cancer. 132:1133–1145. 2013. View Article : Google Scholar
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Wang D and Lippard SJ: Cellular processing
of platinum anti-cancer drugs. Nat Rev Drug Discov. 4:307–320.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barker N, van Es JH, Kuipers J, Kujala P,
van den Born M, Cozijnsen M, Haegebarth A, Korving J, Begthel H,
Peters PJ, et al: Identification of stem cells in small intestine
and colon by marker gene Lgr5. Nature. 449:1003–1007. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanwar SS, Yu Y, Nautiyal J, Patel BB and
Majumdar AP: The Wnt/beta-catenin pathway regulates growth and
maintenance of colonospheres. Mol Cancer. 9:2122010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Arnould S, Hennebelle I, Canal P, Bugat R
and Guichard S: Cellular determinants of oxaliplatin sensitivity in
colon cancer cell lines. Eur J Cancer. 39:112–119. 2003. View Article : Google Scholar
|
|
7
|
Ringel I and Horwitz SB: Studies with RP
56976 (taxotere): A semisynthetic analogue of taxol. J Natl Cancer
Inst. 83:288–291. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sternberg CN, ten Bokkel Huinink WW, Smyth
JF, Bruntsch V, Dirix LY, Pavlidis NA, Franklin H, Wanders S, Le
Bail N and Kaye SB: Docetaxel (Taxotere), a novel taxoid, in the
treatment of advanced colorectal carcinoma: An EORTC Early Clinical
Trials Group Study. Br J Cancer. 70:376–379. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee HH, Leake BF, Teft W, Tirona RG, Kim
RB and Ho RH: Contribution of hepatic organic anion-transporting
polypeptides to docetaxel uptake and clearance. Mol Cancer Ther.
14:994–1003. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
van Herwaarden AE, Wagenaar E, van der
Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk
MA, van Tellingen O, van der Hoorn JW, Rosing H, et al: Knockout of
cytochrome P450 3A yields new mouse models for understanding
xenobiotic metabolism. J Clin Invest. 117:3583–3592. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wils P, Phung-Ba V, Warnery A, Lechardeur
D, Raeissi S, Hidalgo IJ and Scherman D: Polarized transport of
docetaxel and vinblastine mediated by P-glycoprotein in human
intestinal epithelial cell monolayers. Biochem Pharmacol.
48:1528–1530. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai
LY and Hou MF: Side effects after docetaxel treatment in Taiwanese
breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene
polymorphisms. Clin Chim Acta. 404:160–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Murray S, Briasoulis E, Linardou H,
Bafaloukos D and Papadimitriou C: Taxane resistance in breast
cancer: Mechanisms, predictive biomarkers and circumvention
strategies. Cancer Treat Rev. 38:890–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wen K, Fu Z, Wu X, Feng J, Chen W and Qian
J: Oct-4 is required for an antiapoptotic behavior of
chemoresistant colorectal cancer cells enriched for cancer stem
cells: Effects associated with STAT3/Survivin. Cancer Lett.
333:56–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1037. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
O’Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
19
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
20
|
Jordan CT: Cancer stem cell biology: From
leukemia to solid tumors. Curr Opin Cell Biol. 16:708–712. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
An Y and Ongkeko WM: ABCG2: The key to
chemoresistance in cancer stem cells? Expert Opin Drug Metab
Toxicol. 5:1529–1542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
D’Arcangelo M, Todaro M, Salvini J,
Benfante A, Colorito ML, D’Incecco A, Landi L, Apuzzo T, Rossi E,
Sani S, et al: Cancer Stem Cells Sensitivity Assay (STELLA) in
patients with advanced lung and colorectal cancer: A feasibility
study. PLoS One. 10:e01250372015. View Article : Google Scholar :
|
|
23
|
Maugeri-Saccà M, Vigneri P and De Maria R:
Cancer stem cells and chemosensitivity. Clin Cancer Res.
17:4942–4947. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chakrabarty S: Regulation of human
colon-carcinoma cell adhesion to extracellular matrix by
transforming growth factor beta 1. Int J Cancer. 50:968–973. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Whissell G, Montagni E, Martinelli P,
Hernando-Momblona X, Sevillano M, Jung P, Cortina C, Calon A, Abuli
A, Castells A, et al: The transcription factor GATA6 enables
self-renewal of colon adenoma stem cells by repressing BMP gene
expression. Nat Cell Biol. 16:695–707. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang R, Wang G, Song Y, Tang Q, You Q,
Liu Z, Chen Y, Zhang Q, Li J, Muhammand S, et al: Colorectal cancer
stem cell and chemoresistant colorectal cancer cell phenotypes and
increased sensitivity to Notch pathway inhibitor. Mol Med Rep.
12:2417–2424. 2015.PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Liang CC, Park AY and Guan JL: In vitro
scratch assay: A convenient and inexpensive method for analysis of
cell migration in vitro. Nat Protoc. 2:329–333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Saha A, Shree Padhi S, Roy S and Banerjee
B: Method of detecting new cancer stem cell-like enrichment in
development front assay (DFA). J Stem Cells. 9:235–242. 2014.
|
|
30
|
Myint K, Li Y, Paxton J and McKeage M:
Multidrug resistance-associated protein 2 (MRP2) mediated transport
of oxaliplatin-derived platinum in membrane vesicles. PLoS One.
10:e01307272015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Buxhofer-Ausch V, Secky L, Wlcek K,
Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W and
Thalhammer T: Tumor-specific expression of organic
anion-transporting polypeptides: Transporters as novel targets for
cancer therapy. J Drug Deliv. 2013:8635392013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rabik CA, Maryon EB, Kasza K, Shafer JT,
Bartnik CM and Dolan ME: Role of copper transporters in resistance
to platinating agents. Cancer Chemother Pharmacol. 64:133–142.
2009. View Article : Google Scholar :
|
|
33
|
Furuta T, Ueda T, Aune G, Sarasin A,
Kraemer KH and Pommier Y: Transcription-coupled nucleotide excision
repair as a determinant of cisplatin sensitivity of human cells.
Cancer Res. 62:4899–4902. 2002.PubMed/NCBI
|
|
34
|
Garg A and Aggarwal BB: Nuclear
transcription factor-kappaB as a target for cancer drug
development. Leukemia. 16:1053–1068. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yilmaz M and Christofori G: EMT, the
cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev.
28:15–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pang R, Law WL, Chu AC, Poon JT, Lam CS,
Chow AK, Ng L, Cheung LW, Lan XR, Lan HY, et al: A subpopulation of
CD26+ cancer stem cells with metastatic capacity in
human colorectal cancer. Cell Stem Cell. 6:603–615. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Papailiou J, Bramis KJ, Gazouli M and
Theodoropoulos G: Stem cells in colon cancer. A new era in cancer
theory begins. Int J Colorectal Dis. 26:1–11. 2011. View Article : Google Scholar
|
|
38
|
Hermann PC, Bhaskar S, Cioffi M and
Heeschen C: Cancer stem cells in solid tumors. Semin Cancer Biol.
20:77–84. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang J, Wang H, Li Z, Wu Q, Lathia JD,
McLendon RE, Hjelmeland AB and Rich JN: c-Myc is required for
maintenance of glioma cancer stem cells. PLoS One. 3:e37692008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mori R, Ishiguro H, Kuwabara Y, Kimura M,
Mitsui A, Tomoda K, Mori Y, Ogawa R, Katada T, Harata K, et al:
Targeting beta1 integrin restores sensitivity to docetaxel of
esophageal squamous cell carcinoma. Oncol Rep. 20:1345–1351.
2008.PubMed/NCBI
|
|
41
|
Zhang H, Ozaki I, Mizuta T, Matsuhashi S,
Yoshimura T, Hisatomi A, Tadano J, Sakai T and Yamamoto K: Beta
1-integrin protects hepatoma cells from chemotherapy induced
apoptosis via a mitogen-activated protein kinase dependent pathway.
Cancer. 95:896–906. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Schenk PW, Stoop H, Bokemeyer C, Mayer F,
Stoter G, Oosterhuis JW, Wiemer E, Looijenga LH and Nooter K:
Resistance to platinum-containing chemotherapy in testicular germ
cell tumors is associated with downregulation of the protein kinase
SRPK1. Neoplasia. 6:297–301. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gout S, Brambilla E, Boudria A, Drissi R,
Lantuejoul S, Gazzeri S and Eymin B: Abnormal expression of the
pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non
small cell lung carcinoma. PLoS One. 7:e465392012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
el-Akawi Z, Abu-Hadid M, Perez R, Glavy J,
Zdanowicz J, Creaven PJ and Pendyala L: Altered glutathione
metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer
Lett. 105:5–14. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hall MD, Okabe M, Shen DW, Liang XJ and
Gottesman MM: The role of cellular accumulation in determining
sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol
Toxicol. 48:495–535. 2008. View Article : Google Scholar
|
|
46
|
Habel N, Hamidouche Z, Girault I,
Patiño-García A, Lecanda F, Marie PJ and Fromigué O: Zinc
chelation: A metallothionein 2A’s mechanism of action involved in
osteosarcoma cell death and chemotherapy resistance. Cell Death
Dis. 4:e8742013. View Article : Google Scholar
|
|
47
|
L’Espérance S, Popa I, Bachvarova M,
Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression
profiling of paired ovarian tumors obtained prior to and following
adjuvant chemotherapy: Molecular signatures of chemoresistant
tumors. Int J Oncol. 29:5–24. 2006.
|
|
48
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Levêque D and Jehl F: P-glycoprotein and
pharmacokinetics. Anticancer Res. 15:331–336. 1995.PubMed/NCBI
|
|
50
|
Roninson IB: Molecular mechanism of
multidrug resistance in tumor cells. Clin Physiol Biochem.
5:140–151. 1987.PubMed/NCBI
|
|
51
|
She JJ, Zhang PG, Wang X, Che XM and Wang
ZM: Side population cells isolated from KATO III human gastric
cancer cell line have cancer stem cell-like characteristics. World
J Gastroenterol. 18:4610–4617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ceckova M, Vackova Z, Radilova H, Libra A,
Buncek M and Staud F: Effect of ABCG2 on cytotoxicity of platinum
drugs: Interference of EGFP. Toxicol In Vitro. 22:1846–1852. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Qu H, Fang L, Duan L and Long X:
Expression of ABCG2 and p-glycoprotein in residual breast cancer
tissue after chemotherapy and their correlation with
epithelial-mesenchymal transition. Zhonghua Bing Li Xue Za Zhi.
43:236–240. 2014.(In Chinese). PubMed/NCBI
|
|
54
|
Hinoshita E, Uchiumi T, Taguchi K,
Kinukawa N, Tsuneyoshi M, Maehara Y, Sugimachi K and Kuwano M:
Increased expression of an ATP-binding cassette superfamily
transporter, multidrug resistance protein 2, in human colorectal
carcinomas. Clin Cancer Res. 6:2401–2407. 2000.PubMed/NCBI
|
|
55
|
Tamai I: Oral drug delivery utilizing
intestinal OATP transporters. Adv Drug Deliv Rev. 64:508–514. 2012.
View Article : Google Scholar
|
|
56
|
Plasencia C, Martínez-Balibrea E,
Martinez-Cardús A, Quinn DI, Abad A and Neamati N: Expression
analysis of genes involved in oxaliplatin response and development
of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol.
29:225–235. 2006.PubMed/NCBI
|
|
57
|
Damia G, Guidi G and D’Incalci M:
Expression of genes involved in nucleotide excision repair and
sensitivity to cisplatin and melphalan in human cancer cell lines.
Eur J Cancer. 34:1783–1788. 1998. View Article : Google Scholar
|
|
58
|
Selvakumaran M, Pisarcik DA, Bao R, Yeung
AT and Hamilton TC: Enhanced cisplatin cytotoxicity by disturbing
the nucleotide excision repair pathway in ovarian cancer cell
lines. Cancer Res. 63:1311–1316. 2003.PubMed/NCBI
|
|
59
|
Rosell R, Taron M, Barnadas A, Scagliotti
G, Sarries C and Roig B: Nucleotide excision repair pathways
involved in Cisplatin resistance in non-small-cell lung cancer.
Cancer Control. 10:297–305. 2003.PubMed/NCBI
|
|
60
|
David CJ and Manley JL: Alternative
pre-mRNA splicing regulation in cancer: Pathways and programs
unhinged. Genes Dev. 24:2343–2364. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kim SM, Lee SY, Yuk DY, Moon DC, Choi SS,
Kim Y, Han SB, Oh KW and Hong JT: Inhibition of NF-kappaB by
ginsenoside Rg3 enhances the susceptibility of colon cancer cells
to docetaxel. Arch Pharm Res. 32:755–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang CY, Cusack JC Jr, Liu R and Baldwin
AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor
therapy through increased apoptosis by inhibition of NF-kappaB. Nat
Med. 5:412–417. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
63
|
Shen W, Pang H, Liu J, Zhou J, Zhang F and
Liu L, Ma N, Zhang N, Zhang H and Liu L: Epithelial-mesenchymal
transition contributes to docetaxel resistance in human non-small
cell lung cancer. Oncol Res. 22:47–55. 2014. View Article : Google Scholar
|
|
64
|
Mahyar-Roemer M and Roemer K: p21
Waf1/Cip1 can protect human colon carcinoma cells against
p53-dependent and p53-independent apoptosis induced by natural
chemopreventive and therapeutic agents. Oncogene. 20:3387–3398.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Yang AD, Fan F, Camp ER, van Buren G, Liu
W, Somcio R, Gray MJ, Cheng H, Hoff PM and Ellis LM: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Bates RC, DeLeo MJ III and Mercurio AM:
The epithelial-mesenchymal transition of colon carcinoma involves
expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res.
299:315–324. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Na DC, Lee JE, Yoo JE, Oh BK, Choi GH and
Park YN: Invasion and EMT-associated genes are up-regulated in B
viral hepatocellular carcinoma with high expression of CD133-human
and cell culture study. Exp Mol Pathol. 90:66–73. 2011. View Article : Google Scholar
|
|
68
|
Dalerba P, Dylla SJ, Park IK, Liu R, Wang
X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al:
Phenotypic characterization of human colorectal cancer stem cells.
Proc Natl Acad Sci USA. 104:10158–10163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Leinung M, Ernst B, Döring C, Wagenblast
J, Tahtali A, Diensthuber M, Stöver T and Geissler C: Expression of
ALDH1A1 and CD44 in primary head and neck squamous cell carcinoma
and their value for carcinogenesis, tumor progression and cancer
stem cell identification. Oncol Lett. 10:2289–2294. 2015.PubMed/NCBI
|
|
70
|
Sullivan JP, Spinola M, Dodge M, Raso MG,
Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et
al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma
stem cells dependent on notch signaling. Cancer Res. 70:9937–9948.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Maetzel D, Denzel S, Mack B, Canis M, Went
P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, et al: Nuclear
signalling by tumour-associated antigen EpCAM. Nat Cell Biol.
11:162–171. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Amini S, Fathi F, Mobalegi J,
Sofimajidpour H and Ghadimi T: The expressions of stem cell
markers: Oct4, Nanog, Sox2, nucleostemin, Bmi, Zfx, Tcl1, Tbx3,
Dppa4, and Esrrb in bladder, colon, and prostate cancer, and
certain cancer cell lines. Anat Cell Biol. 47:1–11. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Wiktorska M, Sacewicz-Hofman I,
Stasikowska-Kanicka O, Danilewicz M and Niewiarowska J: Distinct
inhibitory efficiency of siRNAs and DNAzymes to β1 integrin subunit
in blocking tumor growth. Acta Biochim Pol. 60:77–82. 2013.
|
